Stockreport

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting [Yahoo! Finance]

Gyre Therapeutics, Inc.  (GYRE) 
PDF filing for Hydronidone and priority review eligibility, subject to formal approval. Gyre Pharmaceuticals plans to submit an NDA in the first half of 2026 and conduct a [Read more]